Community Health Systems Q3 2026 Earnings: Payor Mix Drives a Return to Loss

Community Health Systems (NYSE: CYH) reported Q3 2026 net operating revenue of $2.757 billion, down 10.7% from $3.087 billion a year earlier, while diluted EPS swung to a loss of $0.63 from earnings of $0.96. Same-store revenue and volumes grew, but divestitures, unfavorable payor mix, lower non-patient revenue, and higher costs pushed adjusted EBITDA down 25.5% to $280 million; quarterly operating cash flow nevertheless rose to $155 million.

Core Earnings Data

The consolidated revenue decline for the quarter ended September 30 partly reflected a smaller hospital portfolio. Profitability weakened more sharply than activity at retained facilities, with both operating margin and adjusted EBITDA margin falling from the prior-year period.

Adjusted diluted EPS and adjusted EBITDA are non-GAAP measures. The company said the earnings decline reflected lower adjusted EBITDA and a substantially smaller income-tax benefit, partly offset by lower interest expense and a favorable change in losses from early debt extinguishment.

Operating Performance

The clearest operational split was between consolidated and same-store results. Community Health Systems operated 60 hospitals at quarter-end, compared with 70 a year earlier, while activity increased across the comparable hospital base.

Same-store results include businesses operated in both comparable periods and exclude businesses divested before September 30, 2026. The contrast indicates that portfolio contraction drove much of the headline decline, rather than falling patient activity at retained hospitals.

Same-Store Growth Did Not Translate Into Higher EBITDA

Higher same-store volumes and reimbursement rates provided support, but they were not enough to offset the effects of divestitures, unfavorable payor mix, higher medical specialist fees, and increased supplemental reimbursement program expense. Non-patient revenue also declined because Q3 2025 included a $28 million legal settlement.

This combination explains why same-store revenue increased while adjusted EBITDA fell. The retained hospital base treated more patients, but the mix of reimbursement and higher operating costs reduced the profit generated from that activity.

Profitability, Cash Flow, and the Balance Sheet

Total operating expenses increased to 94.7% of revenue from 92.1%. Other operating expenses were the largest source of margin pressure, rising to 29.3% of revenue from 26.9%, while salaries and benefits edged up to 44.1% from 43.9%.

The bottom-line reversal was also amplified by taxes. The income-tax benefit declined to $3 million from $173 million in Q3 2025. Net interest expense fell to $201 million from $216 million, but it still exceeded the quarter’s $146 million of operating income.

Quarterly operating cash flow more than doubled to $155 million despite the net loss. However, cash flow remained weak over the longer reporting period: operating cash flow for the first nine months of 2026 was negative $55 million, compared with positive $277 million a year earlier.

At September 30, cash and cash equivalents stood at $155 million, down from $260 million at the end of 2025. Long-term debt declined to $9.568 billion from $10.380 billion, while the stockholders’ deficit widened to $1.492 billion from $1.394 billion.

Management Commentary

CEO Kevin J. Hammons said volume trends and cash flow improved sequentially during the quarter. However, payor mix and patient acuity did not develop as management expected because of the challenging macroeconomic environment, weighing on both Q3 results and expectations for the remainder of the year.

Management also continues to invest in quality outcomes, patient satisfaction, physician experience, and employee satisfaction, which it expects to support future financial performance. The release did not quantify the timing or financial contribution of those initiatives.

Recent Insider Transactions

The supplied insider data shows 43,930 shares purchased through two transactions and 40,000 shares sold through one transaction during the last six months, resulting in net purchases of 3,930 shares. Total insider holdings were reported at 20.58 million shares.

The latest identified sale with complete transaction details was made by a director. The aggregate purchase data did not identify the individual buyers.

Other recent records consisted primarily of zero-price stock awards, one stock gift, and two director filings without disclosed transaction details. Those records do not provide comparable open-market purchase or sale values.

Risks Investors Should Watch

• Payor mix and acuity: Management said both were weaker than expected. Continued pressure could prevent higher patient volumes from translating into comparable revenue and EBITDA growth.
• Operating cost pressure: Medical specialist fees, supplemental reimbursement program expenses, and higher other operating expenses reduced margins in Q3.
• Leverage and liquidity: Long-term debt remained at $9.568 billion, quarterly interest expense exceeded operating income, and nine-month operating cash flow was negative despite the Q3 improvement.
• Portfolio contraction: Divestitures reduced consolidated revenue and admissions. Further portfolio changes could continue to create a gap between consolidated and same-store performance.

Conclusion

Community Health Systems’ Q3 2026 results showed improving activity at retained hospitals and stronger quarterly cash flow, but divestitures, unfavorable payor mix, and higher costs reduced consolidated revenue and profitability. The central issue ahead is whether same-store volume growth can produce higher EBITDA and whether the Q3 cash-flow improvement can reverse the negative year-to-date trend while the company continues managing its debt burden.